IBA Reports Half Year 2016 Results
Revenues up 20% - On Track To Meet 2016 Guidance
Louvain-La-Neuve, Belgium, August 25, 2016 - IBA (Ion Beam Applications S.A., EURONEXT), the world's leading provider of proton therapy solutions for the treatment of cancer, today announces its consolidated results for the first half of 2016.
|Sales & Services||145 128||120 997||24 131||19.9%|
|REBITDA||17 970||14 605||3 365||23.0%|
|% of Sales||12.4%||12.1%|
|REBIT||15 133||12 614||2 519||20.0%|
|% of Sales||10.4%||10.4%|
|Net Result||8 297||14 450||-6 153||-42.6%|
|% of Sales||5.7%||11.9%|
H1 Financial Highlights
H1 Business Highlights
Post Period End Highlights
Olivier Legrain, Chief Executive Officer of IBA, commented: " The strong first-half performance has demonstrated the continued momentum of proton therapy growth globally, led by the increasing success of Proteus ® ONE, our unique compact solution. The collaboration with HIL announced earlier this week underlines our commitment to constant innovation, identifying new opportunities and technologies that will enable us to deliver ever higher standards while potentially reducing the costs of treatment."
"As demand for our technology grows, so does the IBA team. We are on course to recruit 400 additional specialists that we have targeted as part of our ambitious growth strategy, with more than 50% already selected."
"The order pipeline for the rest of 2016 is strong. With continued demand for our proton therapy solutions and despite challenging times for our Dosimetry business, we are on track to meet our guidance for the full year."
Conference Call Information:
IBA will host a conference call and webcast today at 16:00 CEST / 15:00 BST / 10:00 EDT / 07:00 PDT. Olivier Legrain, Chief Executive Officer, and Soumya Chandramouli, Chief Financial Officer, will host the call which will be conducted in English. The conference call will be webcast live and can be accessed online at: http://arkadinemea-events.adobeconnect.com/iba . If you would like to participate in the Q&A, please dial (PIN code 76832733#):
Belgium: +32 2 404 03 05
UK: +44 207 750 9926
NL: +31 207 133 488
LU: +352 278 601 66
US: +1 914 885 0779
FR: +33 172 040 033
The webcast presentation will be available on the Company's website shortly after the call.
Third Quarter Business Update : November 17, 2016
Full Year Results 2016 : March 24, 2017
IBA (Ion Beam Applications S.A.) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The Company is the worldwide technology leader in the field of proton therapy, the most advanced form of radiation therapy available today. IBA's proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full scale proton therapy centers as well as compact, single room solutions. In addition, IBA also has a radiation dosimetry business and develops particle accelerators for the medical world and industry.
Headquartered in Belgium and employing about 1,300 people worldwide, IBA has installed solutions across the world. IBA is listed on the pan-European stock exchange EURONEXT. (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB) and more information can be found at: www.iba-worldwide.com
* Proteus ® PLUS and Proteus ® ONE are the brand names of new configurations of the Proteus ® 235
For further information please contact:
Chief Strategy Officer
Chief Financial Officer
+32 10 475 890
Vice-President Corporate Communication
+32 10 475 890
For media and investor enquiries:
Consilium Strategic Communications
Jonathan Birt, Matthew Neal, Ivar Milligan
+44 (0) 20 3709 5700
Rx Communications Group (US)
+ 1 917 322 2571
Last updated on: 26/08/2016
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.